Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics

D Grady1, W Applegate, T Bush

  • 1Department of Epidemiology and Biostatistics, University of California, San Francisco, 94105, USA.

Controlled Clinical Trials
|July 31, 1998
PubMed
Summary

The Heart and Estrogen/progestin Replacement Study (HERS) investigated hormone therapy for women with heart disease. Estrogen plus progestin did not reduce recurrent coronary heart disease events in postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of high-flow nasal oxygen flow rate on gas exchange in apnoeic patients: a randomised controlled trial.

Anaesthesia·2023
Same author

Multistate outbreaks of <i>Salmonella</i> infections linked to imported Maradol papayas - United States, December 2016-September 2017.

Epidemiology and infection·2019
Same author

Lower serum adiponectin level is associated with lipodystrophy among HIV-infected men in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN) study.

HIV medicine·2019
Same author

Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults.

The Journal of frailty & aging·2016
Same author

Habitability: A Review.

Astrobiology·2016
Same author

Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.

Climacteric : the journal of the International Menopause Society·2012

Area of Science:

  • Cardiology
  • Endocrinology
  • Women's Health

Background:

  • Postmenopausal hormone therapy is widely used, but its efficacy and safety for preventing recurrent coronary heart disease (CHD) events in women are not well established.
  • The Heart and Estrogen/progestin Replacement Study (HERS) was initiated to address this critical knowledge gap.

Purpose of the Study:

  • To determine the efficacy and safety of estrogen plus progestin therapy in preventing recurrent coronary heart disease (CHD) events in postmenopausal women with established CHD.
  • To evaluate the impact of hormone therapy on other major CHD endpoints, including revascularization and hospitalization for unstable angina.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 2763 postmenopausal women with CHD.
  • Participants received either conjugated estrogens plus medroxyprogesterone acetate or a placebo daily.

Related Experiment Videos

  • Follow-up averaged 4.2 years, with CHD events meticulously recorded and analyzed.

    • Main Results:

    • Estrogen plus progestin therapy did not significantly reduce the rate of recurrent coronary heart disease (CHD) events (CHD death and nonfatal myocardial infarction) compared to placebo.
    • The study found no significant benefit of hormone therapy in preventing major CHD endpoints in this population.

    Conclusions:

    • Estrogen plus progestin therapy is not effective in preventing recurrent coronary heart disease (CHD) events in postmenopausal women with existing heart disease.
    • These findings have significant implications for the use of hormone therapy in women with cardiovascular disease.